These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 36278195)

  • 1. Effects of CYP2C19 genetic polymorphisms on the cure rates of
    Zhao X; Zhang Z; Lu F; Xiong M; Jiang L; Tang K; Fu M; Wu Y; He B
    Front Pharmacol; 2022; 13():938419. PubMed ID: 36278195
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
    Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.
    Dojo M; Azuma T; Saito T; Ohtani M; Muramatsu A; Kuriyama M
    Dig Liver Dis; 2001 Nov; 33(8):671-5. PubMed ID: 11785712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
    Padol S; Yuan Y; Thabane M; Padol IT; Hunt RH
    Am J Gastroenterol; 2006 Jul; 101(7):1467-75. PubMed ID: 16863547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of
    Morino Y; Sugimoto M; Nagata N; Niikiura R; Iwata E; Hamada M; Kawai Y; Fujimiya T; Takeuchi H; Unezaki S; Kawai T
    Front Pharmacol; 2021; 12():759249. PubMed ID: 34721043
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials.
    Tang HL; Li Y; Hu YF; Xie HG; Zhai SD
    PLoS One; 2013; 8(4):e62162. PubMed ID: 23646118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
    Inaba T; Mizuno M; Kawai K; Yokota K; Oguma K; Miyoshi M; Take S; Okada H; Tsuji T
    J Gastroenterol Hepatol; 2002 Jul; 17(7):748-53. PubMed ID: 12121503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C19 polymorphism influences Helicobacter pylori eradication.
    Kuo CH; Lu CY; Shih HY; Liu CJ; Wu MC; Hu HM; Hsu WH; Yu FJ; Wu DC; Kuo FC
    World J Gastroenterol; 2014 Nov; 20(43):16029-36. PubMed ID: 25473155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of
    Fu J; Sun CF; He HY; Ojha SC; Shi H; Deng CL; Sheng YJ
    Pharmacogenomics; 2021 Aug; 22(13):859-879. PubMed ID: 34414773
    [No Abstract]   [Full Text] [Related]  

  • 10. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
    Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
    Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin.
    Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Nakagawa K; Sugimura H; Ohashi K; Ishizaki T
    Pharmacogenetics; 2001 Jun; 11(4):341-8. PubMed ID: 11434512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.
    Ormeci A; Emrence Z; Baran B; Gokturk S; Soyer OM; Evirgen S; Akyuz F; Karaca C; Besisik F; Kaymakoglu S; Ustek D; Demir K
    Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):879-85. PubMed ID: 27010145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
    Gawrońska-Szklarz B; Wrześniewska J; Starzyńska T; Pawlik A; Safranow K; Ferenc K; Droździk M
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):375-9. PubMed ID: 15976989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole.
    Lee JH; Jung HY; Choi KD; Song HJ; Lee GH; Kim JH
    Gut Liver; 2010 Jun; 4(2):201-6. PubMed ID: 20559522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism.
    Miyoshi M; Mizuno M; Ishiki K; Nagahara Y; Maga T; Torigoe T; Nasu J; Okada H; Yokota K; Oguma K; Tsuji T
    J Gastroenterol Hepatol; 2001 Jul; 16(7):723-8. PubMed ID: 11446878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection.
    McNicholl AG; Linares PM; Nyssen OP; Calvet X; Gisbert JP
    Aliment Pharmacol Ther; 2012 Sep; 36(5):414-25. PubMed ID: 22803691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of CYP2C19 Gene Polymorphisms on Proton Pump Inhibitor, Amoxicillin, and Levofloxacin Triple Therapy for Eradication of Helicobacter Pylori.
    Lin YA; Wang H; Gu ZJ; Wang WJ; Zeng XY; Du YL; Ying SS; Zhang BH
    Med Sci Monit; 2017 Jun; 23():2701-2707. PubMed ID: 28577017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
    Furuta T; Shirai N; Sugimoto M; Nakamura A; Hishida A; Ishizaki T
    Drug Metab Pharmacokinet; 2005 Jun; 20(3):153-67. PubMed ID: 15988117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
    Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
    Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of CYP2C19 polymorphism in Bogotá, Colombia: The first report of allele *17.
    Arévalo-Galvis A; Otero-Regino WA; Ovalle-Celis GN; Rodríguez-Gómez ER; Trespalacios-Rangel AA
    PLoS One; 2021; 16(1):e0245401. PubMed ID: 33503046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.